PPT-The Evolution of Cardiovascular Outcomes Trials in T2DM Over the Years

Darren K McGuire MD MHSc Professor of Medicine University of Texas Southwestern Medical Center Conflict of Interest Disclosure Clinical Trials Leadership Takeda Merck Astra Zeneca Janssen. 20 1027200 1048830 1054860 1081860 1126920 1137390 1180200 1192470 1229340 1282710 O7 826440 864840 882600 896730 922290 947580 976770 1005900 1035120 1126920 1204380 O6 612540 672960 717120 717120 719850 750720 754770 754770 797670 873510 918030 O5 By: Jeremy Clark, Megan Windland, and Tiana Nater. Negative Effects of Cardiovascular disease. Eating foods that are high in saturated fats and cholesterol may cause plaque to form on artery walls. . Gary Michael Idelchik, MD, FACC. April 15, . 2015. Disclosures. I have nothing to disclose.. Outline. What is/are. … . What is Cardiovascular Disease and its manifestations?. What is Coronary Artery Disease (. Chapter 5. Thomas . Ransom, Ronald Goldenberg, Amanda . Mikalachki. , Ally . PH . Prebtani. , . Zubin. . Punthakee. Canadian Diabetes Association 2013 Clinical Practice Guidelines. Key Points. At this time, there are no safe and effective strategies to prevent T1DM. Christina McConnell, PGY-3. Which of the following is NOT one of the diagnostic criteria for lupus?. Biopsy proven lupus nephritis with a positive ANA. Hemolytic anemia. Psychosis. Single joint swelling. Agenda. Introduction/Background. CV Safety With Intensive Glucose Lowering. Regulatory Request for CV Safety Trials. ORIGIN Trial. DEVOTE: . Study Drugs. Rationale for DEVOTE Trial. DEVOTE Baseline Characteristics. Add on to insulin. EFFICACY AND TOLERABILITY. OF GLP-1 RECEPTOR AGONISTS. AND DPP-4 INHIBITORS AS ADDON THERAPY TO INSULIN . Complementing Insulin Therapy to Achieve Glycemic. Control. Anthony H. Barnett . FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. Introduction/Background. Bariatric (Metabolic) Surgery Modalities. Multiple Hormonal Signals Interpreted by the CNS Influence Appetite. Obesity. and T2DM: Key Correlations. Medical Complications of Obesity. CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. Backgrounde International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM) []. People with diabetes comprise 8.8% by Sun H. Kim, MD MS. Associate Professor of Medicine. Division of Endocrinology, Gerontology, and Metabolism. March 29, 2022. This Community Health Talk Series was made possible through the generous support of the Vincent V.C. Woo Memorial Foundation.. Professor Julia . Brown. Leeds Institute of Clinical Trials Research, University of Leeds. Introduction. First clinical trial in 1747, James Lind. Clinical trials are gold standard for the evaluation of new treatments/interventions in health care . NT-. proBNP. . concentrations identify . T2DM . patients at high risk for major . CV . events. A subanalysis of the EXAMINE study (N=1,306 in each NT-proBNP group) . Primary endpoint: CV . death, non-fatal myocardial .